case_images: PMC7970699_01
case_images: Free light chain concentration of the patient in different treatment stages.
case_images: 10.1177_2040620721989578-fig1.jpg
case_images: PMC7970699_01_10.1177_2040620721989578-fig1.jpg
case_images: fig1-2040620721989578
case_images: Minimal residual disease (MRD) was negative on BM FCM, and the serum FLC ratio returned to normal (Figure 1).
case_images: Immune cell dynamics using flow cytometry before and after daratumumab-based therapy.. Rapid downregulation of NK cells, B cells, Bregs, and Tregs can be noted after 4 weeks of daratumumab-based therapy. Meanwhile, the proportion of T cells is increased, with a higher increase of CD8+ compared with CD4+ T cells.. Bregs, regulatory B cells; Tregs, regulatory T cells; NK, natural killer.
case_images: 10.1177_2040620721989578-fig2.jpg
case_images: PMC7970699_01_10.1177_2040620721989578-fig2.jpg
case_images: fig2-2040620721989578
case_images: Besides the rapid clearance of plasma cells, both natural killer (NK) cells, B cells and CD38+ regulatory T cells (Tregs) were significantly downregulated, and the proportion of T cells quickly increased, with a higher proportion of CD8+ than CD4+ T cells (Figure 2).